Interesting Images68Ga-DOTAGA-IAC PET/CT for Imaging Metastatic and Recurrent Adrenocortical Carcinoma A Case SeriesPandey, Somit PhD Scholar∗; Walia, Rama MD†; Kumar, Rajender MD∗; Chopra, Sejal PhD Scholar∗; Rana, Nivedita PhD∗; Chatterjee, Debajyoti MD, DM‡; Satz, Stanley PhD§; Mittal, Bhagwant Rai MD, DNB∗; Shukla, Jaya PhD∗ Author Information From the ∗Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India †Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India ‡Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India §Advanced Innovative Partners, Inc, Miami, FL. Received for publication June 8, 2022; revision accepted October 13, 2022. Conflicts of interest and sources of funding: none declared. This study was funded by the Advanced Innovative Partners, Inc, USA. Correspondence to: Jaya Shukla, PhD, Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India. E-mail: [email protected]. Clinical Nuclear Medicine 48(2):p e95-e98, February 2023. | DOI: 10.1097/RLU.0000000000004497 Buy Metrics Abstract Adrenocortical carcinoma (ACC) is a rare malignancy with a prevalence of 1 to 2 cases/million/year. The diagnosis depends upon endocrine workup followed by imaging with CT, MRI, and 18F-FDG PET/CT. The treatment includes surgical resection, debulking surgery, chemotherapy, and radiotherapy. However, patients do not respond well to any of the available therapies. We present noninvasive imaging of histopathology-proven ACC patients using 68Ga-DOTAGA-IAC PET/CT, specific for integrin αvβ3. 68Ga-DOTAGA-IAC PET/CT 45 minutes after IV injection showed a decent tumor-to-background ratio and could be used as a promising radiotracer for metastatic and recurrent ACC. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.